{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:08Z","timestamp":1793660408261,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":480,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"The Danish Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Aase and Einar Danielsen Foundation"},{"name":"The Beckett Foundation"},{"name":"Herlev and Gentofte Hospital Research Council"},{"name":"The Danish Council for Independent Research","award":["4183-00597B"],"award-info":[{"award-number":["4183-00597B"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1093\/annonc\/mdy139","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T06:40:28Z","timestamp":1524206428000},"page":"1575-1581","source":"Crossref","is-referenced-by-count":71,"title":["T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression"],"prefix":"10.1016","volume":"29","author":[{"given":"R.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.H.","family":"Borch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Draghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gokuldass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.H.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kongsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.W.","family":"Westergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.D.","family":"Radic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"H\u00f6lmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"M.","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1093\/annonc\/mdy139_bb0010","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy139_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PPO.0000000000000240","article-title":"Adoptive cell therapy for metastatic melanoma","volume":"23","author":"Merhavi-Shoham","year":"2017","journal-title":"Cancer J"},{"issue":"1","key":"10.1093\/annonc\/mdy139_bb0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"13","key":"10.1093\/annonc\/mdy139_bb0025","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/0959-8049(93)90542-N","article-title":"The effect of alpha and gamma interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro","volume":"29","author":"Angus","year":"1993","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy139_bb0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1084\/jem.178.5.1655","article-title":"Interferon alpha increases the frequency of interferon gamma-producing human cd4+ T cells","volume":"178","author":"Brinkmann","year":"1993","journal-title":"J Exp Med"},{"issue":"15","key":"10.1093\/annonc\/mdy139_bb0035","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer res"},{"issue":"18","key":"10.1093\/annonc\/mdy139_bb0040","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/0008-5472.CAN-14-2956","article-title":"Aberrant expression of MHC class II in melanoma attracts inflammatory tumor specific CD4+ T cells which dampen CD8+ T cell antitumor reactivity","volume":"75","author":"Donia","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdy139_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"issue":"7528","key":"10.1093\/annonc\/mdy139_bb0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdy139_bb0055","first-page":"56","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"7637","key":"10.1093\/annonc\/mdy139_bb0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"7528","key":"10.1093\/annonc\/mdy139_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"Suppl 39","key":"10.1093\/annonc\/mdy139_bb0070","first-page":"v605","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy139_bb0075","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2017.35.15_suppl.3004","article-title":"Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1\/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients","volume":"35","author":"Fong","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl_15","key":"10.1093\/annonc\/mdy139_bb0080","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2017.35.15_suppl.3014","article-title":"Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy","volume":"35","author":"Curti","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy139_bb0085","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers basedon T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdy139_bb0090","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-iniltrating lymphocyt cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J Immunother"},{"issue":"17","key":"10.1093\/annonc\/mdy139_bb0095","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6230","key":"10.1093\/annonc\/mdy139_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdy139_bb0105","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Comms"},{"issue":"3","key":"10.1093\/annonc\/mdy139_bb0110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2011.37.5394","article-title":"Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma","volume":"30","author":"Tarhini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"85","key":"10.1093\/annonc\/mdy139_bb0115","first-page":"1","article-title":"A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma","volume":"4","author":"Brohl","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdy139_bb0120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00262-011-1004-8","article-title":"Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha","volume":"60","author":"Verdegaal","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"10.1093\/annonc\/mdy139_bb0125","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy139_bb0130","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2017.35.15_suppl.3045","article-title":"Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy","volume":"35","author":"Sarnaik","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy139_bb0135","unstructured":"Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial; http:\/\/www.iovance.com\/wp-content\/uploads\/2017\/11\/SITC2017_Melanoma_poster_FINAL_NSDE_PRINT_7Nov2017 (1 May 2018, date last accessed)."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdy139\/25009114\/mdy139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:39:09Z","timestamp":1624696749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419321003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0923753419321003"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy139","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}